Delving into the Latest Updates on Recombinant humanized anti-IL17A monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

重组人源化抗IL17A单克隆抗体 (上海三生国健)

Target

IL-17A

Mechanism

IL-17A inhibitors(Interleukin 17A inhibitors)

Therapeutic Areas

Immune System DiseasesSkin and Musculoskeletal DiseasesInfectious Diseases

Active Indication

Plaque psoriasisNon-radiographic axial spondyloarthritisAnkylosing Spondylitis+ [1]

Inactive Indication-

Originator Organization-

Active Organization

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

3SBio, Inc.

Inactive Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Unbiased informatics approaches have the potential to generate insights into uncharacterized signaling pathways in human disease.In this study, we generated longitudinal transcriptomic profiles of plaque psoriasis lesions from patients enrolled in a clin. trial of the anti-IL17A antibody ixekizumab (IXE).This dataset was then computed against a curated matrix of over 700 million data points derived from published psoriasis and signaling node perturbation transcriptomic and chromatin immunoprecipitation-sequencing datasets.We observed substantive enrichment within both psoriasis-induced and IXE-repressed gene sets of transcriptional targets of members of the MuvB complex, a master regulator of the mitotic cell cycle.These gene sets were similarly enriched for pathways involved in the regulation of the G2/M transition of the cell cycle.Moreover, transcriptional targets for MuvB nodes were strongly enriched within IXE-repressed genes whose expression levels correlated strongly with the extent and severity of the psoriatic disease.In models of human keratinocyte proliferation, genes encoding MuvB nodes were transcriptionally repressed by IXE, and depletion of MuvB nodes reduced cell proliferation.Finally, we made the expression and regulatory networks that supported this study available as a freely accessible, cloud-based hypothesis generation platform.Our study positions inhibition of MuvB signaling as an important determinant of the therapeutic impact of IXE in psoriasis.

03 Aug 2022·Infectious Diseases

Blockade of interleukin seventeen (IL-17A) with secukinumab in hospitalized COVID-19 patients – the BISHOP study

Article

Author: Forestiero, Francisco ; Souza, Renan Pedra ; Medeiros, Amanda Fonseca ; Aguiar, Renato Santana ; Guimarães, Henrique Cerqueira ; Tunala, Roberto ; Teixeira, Mauro Martins ; Costa e Silva, Alessandra Dias ; Oliveira, Argenil José de Assis ; Sousa, Denise ; da Cruz Lage, Ricardo ; Nogueira Sá, Antônio Tolentino ; Lobê, Samara Quadros ; Resende, Gustavo Gomes ; Gomes, Isabella Coelho ; Bueno Filho, Julio Silvio Souza

BACKGROUNDPatients with severe COVID-19 seem to evolve with a compromised antiviral response and hyperinflammation. Neutrophils are critical players in COVID-19. IL-17A plays a major role in protection against extracellular pathogens and neutrophil attraction/activation. We hypothesized that secukinumab, an anti-IL17A monoclonal antibody, could prevent the deleterious hyperinflammation in COVID-19.METHODSBISHOP was a randomized, open-label, single-centre, phase-II controlled trial. Fifty adult patients hospitalized with PCR-positive Covid-19, were randomized 1:1 to receive 300 mg of secukinumab subcutaneously at day-0 plus standard of care (group A) or standard of care alone (group B). A second dose of 300 mg of secukinumab could be administered on day-7, according to staff judgement. The primary endpoint was ventilator-free days at day-28 (VFD-28). Secondary efficacy and safety outcomes were also explored.RESULTSAn intention-to-treat analysis showed no difference in VFD-28: 23.7 (95%CI 19.6-27.8) in group A vs. 23.8 (19.9-27.6) in group B, p = .62; There was also no difference in hospitalization time, intensive care unit demand and the incidence of circulatory shock, acute kidney injury, fungal or bacterial co-infections. There was no difference in the incidence of severe adverse events. Pulmonary thromboembolism occurred only in males and was less frequent in secukinumab-treated patients (4.2% vs. 26.2% p = .04). There was one death in each group. Upper airway viral clearance was also similar in both groups.CONCLUSIONThe efficacy of secukinumab in the treatment of Covid19 was not demonstrated. Secukinumab decreased pulmonary embolism in male patients. There was no difference between groups in adverse events and no unexpected events were observed.

01 May 2021·Research in Veterinary ScienceQ3 · AGRICULTURAL & FORESTRY SCIENCE

Recombinant bovine IL17A acts as an adjuvant for bovine herpesvirus vaccine

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Santos, Francisco Denis Souza ; Rodrigues, Paulo Ricardo Centeno ; Piraine, Renan Eugênio Araujo ; Gonçalves, Vitória Sequeira ; Conrad, Neida Lucia ; Brasil, Carolina Litchina ; Leite, Fábio Pereira Leivas ; Dos Santos Junior, Alceu Gonçalves

The Bovine herpes virus type 5 glycoprotein D (gD) is essential for viral penetration into host permissive cells. The Herpes virus gD glycoprotein has been used for bovine immunization, being efficient in reduction of viral replication, shedding and clinical signs, however sterilizing immunity is still not achieved. Recombinant subunit vaccines are, in general, poorly immunogenic requiring additional adjuvant components. Interleukin 17A (IL17A) is a pro-inflammatory cytokine produced by T helper 17 cells that mediate mucosal immunity. IL17 production during vaccine-induced immunity is a requirement for mucosal protection to several agents. In this study, we investigated the potential of a recombinant IL17A to act as an adjuvant for a recombinant BoHV-5 glycoprotein D vaccine in cattle. Three cattle groups were divided as: group 1) rgD5 + alumen + rIL-17A; 2) rgD5 + alumen; and 3) PBS + alumen. The cattle (3 per group) received two doses of their respective vaccines at an interval of 21 days. The group that received rIL17 in its vaccine formulation at the 7th day after the prime immunization had significant higher levels of specific rgD-IgG than the alumen group. Addition of rIL17 also led to a significant fold increase in specific anti-rgD IgG and neutralizing antibodies to the virus, respectively, when compared with the alumen group. Cells stimulated with rIL17A responded with IL17 transcription, as well IL2, IL4, IL10, IL15, Bcl6 and CXCR5. Our findings suggest that the rIL17A has adjuvant potential for use in vaccines against BoHV-5 as well as potentially other pathogens of cattle.

100 Deals associated with Recombinant humanized anti-IL17A monoclonal antibody(Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Plaque psoriasis	Phase 3	CN	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	03 Jan 2023
Non-radiographic axial spondyloarthritis	Phase 2	CN	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	18 Mar 2024
Ankylosing Spondylitis	Phase 2	CN	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	27 Feb 2024
Autoimmune Diseases	Phase 2	CN	3SBio, Inc.	30 Jan 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05536726 (NEWS) Manual	Phase 3	Plaque psoriasis	-	608：160 mg W0+80 mg Q2W+80mg Q4W	(tbaikzaxjf) = fewkamrijq qvtoladjrt (veatdpcmen ) Met View more	Positive	02 Aug 2024
				608：160 mg Q4W+160mg Q8W	(tbaikzaxjf) = mxvdukzfuw qvtoladjrt (veatdpcmen ) Met View more